Viatris News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

18.05.23	ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
17.05.23	Viatris to Participate in Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
16.05.23	Viatris Publishes Sustainability Report Showcasing 2022 Progress on Building Sustainable Access to Medicine (PR Newswire)
08.05.23	Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update (RTTNews)
08.05.23	Viatris Inc. Q1 Income Falls (RTTNews)
08.05.23	Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] (PR Newswire)
24.04.23	Viatris and Mapi Pharma to Highlight Latest Results of Multiple Sclerosis Research at American Academy of Neurology 75th Annual Meeting (PR Newswire)
12.04.23	Viatris to Report First Quarter 2023 Financial Results on May 8, 2023 (PR Newswire)
06.04.23	NCD Academy Launches New Health Equity and Social Determinants of Health Course (PR Newswire)
31.03.23	Viatris Wins Summary Judgment in New York Securities Class Action (PR Newswire)
27.02.23	Viatris Names Scott Smith CEO, Succeeding Michael Goettler, With Effect From April 1 (RTTNews)
27.02.23	Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023 (PR Newswire)
27.02.23	Viatris Sees Weak Revenues, Adj. EBITDA In FY23 - Update (RTTNews)
27.02.23	Viatris Inc. Q4 Earnings Summary (RTTNews)
27.02.23	Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance (PR Newswire)
15.02.23	Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 (PR Newswire)
03.01.23	Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division (PR Newswire)
29.12.22	Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors (PR Newswire)
23.12.22	Viatris Inc. to Participate in 41st Annual J.P. Morgan Healthcare Conference (PR Newswire)
14.12.22	Viatris Announces Donations Totaling $1 Million to Provide Aid Supporting Access to Healthcare, Food Security and Water Stewardship (PR Newswire)
14.12.22	Viatris Announces Approval of Emissions Reduction Targets by the Science Based Target initiative (SBTi) (PR Newswire)
13.12.22	Calliditas To Work With Viatris To Bring Nefecon To Japanese Patients (RTTNews)
13.12.22	Shield Therapeutics To Work With Viatris To Bring Accrufer In The U.S. (RTTNews)
29.11.22	Viatris Completes Biosimilars Transaction with Biocon Biologics (PR Newswire)
18.11.22	Viatris Named U.S. In-House Legal Team of the Year for Intellectual Property Litigation by LMG Life Sciences (PR Newswire)
10.11.22	Viatris, Kindeva Announce U.S. Court's Invalidation Of AstraZeneca's Symbicort Patent (RTTNews)
10.11.22	Viatris Wins Court Decision Invalidating AstraZeneca's Symbicort® Patent (PR Newswire)
07.11.22	Viatris To Acquire Oyster Point And Famy Life Sciences To Create Ophthalmology Franchise (RTTNews)
07.11.22	Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event (PR Newswire)
07.11.22	Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update (RTTNews)
07.11.22	Viatris Inc. Profit Climbs In Q3 (RTTNews)
07.11.22	Viatris Reports Strong Third Quarter 2022 Results (PR Newswire)
24.10.22	Viatris to Report Financial Results for the Third Quarter 2022 and Provide an Update on its February 28 Investor Event on November 7, 2022 (PR Newswire)
11.10.22	Viatris Named to Forbes' Annual List of the World's Best Employers for the Second Year in a Row (PR Newswire)
22.09.22	U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris (RTTNews)
06.09.22	Viatris Inc. to Participate in BofA Global Research Global Healthcare Conference (PR Newswire)
08.08.22	Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update (RTTNews)
08.08.22	Viatris Inc. Q2 Earnings Summary (RTTNews)
08.08.22	Viatris Reports Strong Second Quarter 2022 Results (PR Newswire)
07.07.22	Mylan Pharma Recalls Unbranded Insulin Glargine Injection Pens (RTTNews)
01.07.22	Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022 (PR Newswire)
20.05.22	Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference (PR Newswire)
16.05.22	Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals (PR Newswire)
09.05.22	Viatris Maintains FY22 Revenue Outlook, Declares Dividend - Update (RTTNews)
09.05.22	Viatris Inc. Q1 Earnings Summary (RTTNews)
09.05.22	Viatris Reports Strong First-Quarter 2022 Results (PR Newswire)
08.04.22	Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022 (PR Newswire)
30.03.22	Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19 (PR Newswire)
18.03.22	Viatris Says Defeats Biogen's Attempt To Revive Tecfidera Patent (RTTNews)
17.03.22	Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

24.12.24		Aufschläge in New York: S&P 500 verbucht zum Handelsende Zuschläge
24.12.24		Optimismus in New York: So entwickelt sich der S&P 500 am Nachmittag
09.12.24		S&P 500-Titel Viatris-Aktie: So hoch ist die Dividende von Viatris
07.11.24		Pluszeichen in New York: S&P 500 zum Handelsende auf grünem Terrain
07.11.24		Börse New York in Grün: Am Donnerstagnachmittag Gewinne im S&P 500
07.11.24		S&P 500 aktuell: S&P 500 präsentiert sich am Mittag fester
07.11.24		Gute Stimmung in New York: S&P 500 zum Handelsstart im Aufwind
20.09.24		Schwacher Handel in New York: S&P 500 verbucht schlussendlich Verluste

24.12.24

Aufschläge in New York: S&P 500 verbucht zum Handelsende Zuschläge

24.12.24

Optimismus in New York: So entwickelt sich der S&P 500 am Nachmittag

09.12.24

S&P 500-Titel Viatris-Aktie: So hoch ist die Dividende von Viatris

07.11.24

Pluszeichen in New York: S&P 500 zum Handelsende auf grünem Terrain

07.11.24

Börse New York in Grün: Am Donnerstagnachmittag Gewinne im S&P 500

07.11.24

S&P 500 aktuell: S&P 500 präsentiert sich am Mittag fester

07.11.24

Gute Stimmung in New York: S&P 500 zum Handelsstart im Aufwind

20.09.24

Schwacher Handel in New York: S&P 500 verbucht schlussendlich Verluste

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Viatris Inc Registered Shs

Aktien Top/Flop

Viatris Peer Group Nachrichten

Meistgelesene Nachrichten